These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 31549585)

  • 21. Imiquimod Exerts Antitumor Effects by Inducing Immunogenic Cell Death and Is Enhanced by the Glycolytic Inhibitor 2-Deoxyglucose.
    Huang SW; Wang ST; Chang SH; Chuang KC; Wang HY; Kao JK; Liang SM; Wu CY; Kao SH; Chen YJ; Shieh JJ
    J Invest Dermatol; 2020 Sep; 140(9):1771-1783.e6. PubMed ID: 32035924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant Lactaptin Induces Immunogenic Cell Death and Creates an Antitumor Vaccination Effect in Vivo with Enhancement by an IDO Inhibitor.
    Troitskaya O; Varlamov M; Nushtaeva A; Richter V; Koval O
    Molecules; 2020 Jun; 25(12):. PubMed ID: 32560527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of indoleamine 2,3-dioxygenase suppresses NK cell activity and accelerates tumor growth.
    Kai S; Goto S; Tahara K; Sasaki A; Kawano K; Kitano S
    J Exp Ther Oncol; 2003; 3(6):336-45. PubMed ID: 14678522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate.
    Muller AJ; DuHadaway JB; Jaller D; Curtis P; Metz R; Prendergast GC
    Cancer Res; 2010 Mar; 70(5):1845-53. PubMed ID: 20160032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design and Synthesis of Indoleamine 2,3-Dioxygenase 1 Inhibitors and Evaluation of Their Use as Anti-Tumor Agents.
    Wen H; Liu Y; Wang S; Wang T; Zhang G; Chen X; Li Y; Cui H; Lai F; Sheng L
    Molecules; 2019 Jun; 24(11):. PubMed ID: 31195673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blockage of the IDO1 pathway by charge-switchable nanoparticles amplifies immunogenic cell death for enhanced cancer immunotherapy.
    Shi M; Zhang J; Wang Y; Han Y; Zhao X; Hu H; Qiao M; Chen D
    Acta Biomater; 2022 Sep; 150():353-366. PubMed ID: 35843594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy.
    Brochez L; Chevolet I; Kruse V
    Eur J Cancer; 2017 May; 76():167-182. PubMed ID: 28324751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model.
    Yue EW; Douty B; Wayland B; Bower M; Liu X; Leffet L; Wang Q; Bowman KJ; Hansbury MJ; Liu C; Wei M; Li Y; Wynn R; Burn TC; Koblish HK; Fridman JS; Metcalf B; Scherle PA; Combs AP
    J Med Chem; 2009 Dec; 52(23):7364-7. PubMed ID: 19507862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer immunogenic cell death via photo-pyroptosis with light-sensitive Indoleamine 2,3-dioxygenase inhibitor conjugate.
    Lu Y; Xu F; Wang Y; Shi C; Sha Y; He G; Yao Q; Shao K; Sun W; Du J; Fan J; Peng X
    Biomaterials; 2021 Nov; 278():121167. PubMed ID: 34624752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA.
    Yen MC; Lin CC; Chen YL; Huang SS; Yang HJ; Chang CP; Lei HY; Lai MD
    Clin Cancer Res; 2009 Jan; 15(2):641-9. PubMed ID: 19147770
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanoscale Reduced Graphene Oxide-Mediated Photothermal Therapy Together with IDO Inhibition and PD-L1 Blockade Synergistically Promote Antitumor Immunity.
    Yan M; Liu Y; Zhu X; Wang X; Liu L; Sun H; Wang C; Kong D; Ma G
    ACS Appl Mater Interfaces; 2019 Jan; 11(2):1876-1885. PubMed ID: 30582788
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Indoleamine 2,3-dioxygenase, an emerging target for anti-cancer therapy.
    Liu X; Newton RC; Friedman SM; Scherle PA
    Curr Cancer Drug Targets; 2009 Dec; 9(8):938-52. PubMed ID: 20025603
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chromomycin A
    Florêncio KGD; Edson EA; Fernandes KSDS; Luiz JPM; Pinto FDCL; Pessoa ODL; Cunha FQ; Machado-Neto JA; Wilke DV
    Front Immunol; 2022; 13():941757. PubMed ID: 36439184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor Microenvironment-Specific Driven Nanoagents for Synergistic Mitochondria Damage-Related Immunogenic Cell Death and Alleviated Immunosuppression.
    Qian Y; Chen W; Wang M; Xie Y; Qiao L; Sun Q; Gao M; Li C
    Small Methods; 2024 Jul; 8(7):e2301231. PubMed ID: 38126694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Micellar nano-carriers for the delivery of STAT3 dimerization inhibitors to melanoma.
    Soleimani AH; Garg SM; Paiva IM; Vakili MR; Alshareef A; Huang YH; Molavi O; Lai R; Lavasanifar A
    Drug Deliv Transl Res; 2017 Aug; 7(4):571-581. PubMed ID: 28290050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma.
    Inaba T; Ino K; Kajiyama H; Yamamoto E; Shibata K; Nawa A; Nagasaka T; Akimoto H; Takikawa O; Kikkawa F
    Gynecol Oncol; 2009 Nov; 115(2):185-92. PubMed ID: 19665763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference.
    Zheng X; Koropatnick J; Li M; Zhang X; Ling F; Ren X; Hao X; Sun H; Vladau C; Franek JA; Feng B; Urquhart BL; Zhong R; Freeman DJ; Garcia B; Min WP
    J Immunol; 2006 Oct; 177(8):5639-46. PubMed ID: 17015752
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Knockdown of indoleamine 2, 3-dioxygenase 2 (IDO2)gene inhibits tumor growth and enhances immune function in mice bearing melanoma].
    Liu Y; Liu H; Xiang Y; Chen X; Xu P; Min W
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Dec; 33(12):1605-1609. PubMed ID: 29382418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 4-Bromophenylhydrazinyl benzenesulfonylphenylureas as indoleamine 2,3-dioxygenase inhibitors with in vivo target inhibition and anti-tumor efficacy.
    Lin SY; Yeh TK; Song JS; Hung MS; Cheng MF; Liao FY; Li AS; Cheng SY; Lin LM; Chiu CH; Wu MH; Lin YJ; Hsiao W; Sun M; Wang YH; Huang CH; Tang YC; Chang HH; Huang ZT; Chao YS; Shih C; Pan SL; Wu SY; Kuo CC; Ueng SH
    Bioorg Chem; 2018 Apr; 77():600-607. PubMed ID: 29494816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Research progress of indoleamine 2,3-dioxygenase inhibitors.
    Jiang T; Sun Y; Yin Z; Feng S; Sun L; Li Z
    Future Med Chem; 2015; 7(2):185-201. PubMed ID: 25686005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.